Research & Development

Lilly to acquire CrossBridge Bio for up to $300m

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash, comprising an upfront payment and a milestone payment tied to specified development progress.

Travere Therapeutics gains FDA approval for sparsentan in FSGS

Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce proteinuria in adult and paediatric patients aged eight years and above with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.

Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation

Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and commercialisation of bofanglutide injection in South Korea.

EverSea Medicines to acquire Hasten Biopharmaceuticals

Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia).

Jeito Capital secures over $1.2bn for new biopharma investments

Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), thereby establishing a significant new milestone for investment in European Biopharma.

RoosterBio and MineBio team up to expand MSC solutions access in China

RoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to scalable, research-grade and current good manufacturing practice (cGMP)-grade mesenchymal stem cell (MSC) and exosome bioprocessing solutions across China.

Halozyme and Vertex sign deal for Hypercon technology

Halozyme Therapeutics’ subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former’s Hypercon technology.

Apnimed obtains up to $150m in funds for commercial launch of AD109

Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) to support the planned launch of AD109.